Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Susceptibility-Guided vs Empirical Therapy for H. pylori Rescue
NCT03658746Phase 4Completed
- Sponsor
- Shandong University
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin and 2 more in Helicobacter pylori infection (2 arms), sponsored by Shandong University. Primary endpoint: Eradication rates at 6 months. Started Jan 2019; status: completed.
02
Drugs
amoxicillinclarithromycinmetronidazoletinidazolelevofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03658746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658746.